1 / 41

Gestational Trophoblastic Disease (GTD)

Gestational Trophoblastic Disease (GTD). By Ahmed Refaat Abd ELzaher Assistant Lecturer of Medical Oncology South Egypt Cancer Institute 2015. GTD Overview. Heterogeneous group of related lesions Arise from abnormal proliferation of trophoblast of the placenta

Télécharger la présentation

Gestational Trophoblastic Disease (GTD)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Gestational Trophoblastic Disease (GTD) ByAhmed Refaat Abd ELzaherAssistant Lecturer of Medical OncologySouth Egypt Cancer Institute2015

  2. GTD Overview • Heterogeneous group of related lesions • Arise from abnormal proliferation of trophoblast of the placenta • Can follow any gestational event – abortion, miscarriage, ectopic, normal pregnancy • Unique because the maternal lesions arise from fetal (not maternal) tissue • Most GTD lesions produce (B-hCG) • Can be cured even in the presence of widespread metastases

  3. Overview Hydatidiform Mole: • Complete • Partial ** Benign Gestational Trophoblastic Neoplasia (GTN): • Persistent/Invasive Mole • Choriocarcinoma • Placental-Site Trophoblastic Tumor (PSTT) ** Malignant

  4. Relationship of HM. IM. CH hydatidiform therapeutic or molespontaneous abortion term pregnancy ectopic invasion mole choriocarcinoma.

  5. Hydatidiform mole

  6. Hydatidiform Mole • North America: 0.6-1.1 per 1000 pregnancies • Asia: 2-10 per 1000 (3x Western countries) • Difference possibly related low dietary intake of carotene (vitamin A deficiency) and animal fat • More common at reproductive extremes in age (>35y or <20y)

  7. Hydatidiform Mole Risk Factors: • History of previous GTD • If one previous mole, 1% chance of recurrence (vs. 0.1% in general population) • If 2 previous moles, risk of recurrence increases to 16-28% • Smoking • Vitamin A deficiency • Blood type: • A or AB are at slightly higher risk than those with type B or O

  8. Hydatidiform mole • Complete mole 23X 23X 23X sperm empty egg 46,XX 23Y 23X 23X 23Y sperm sperm empty egg 46,XY

  9. Hydatidiform mole • Partial mole 23X 23Y 23X 23X 23X 23Y sperm sperm normal egg 69,XXY 23X 23X 23X 23X 23X 23X sperm sperm Normal egg 69,XXX

  10. Hydatidiform Mole Clinical Manifestations: • Vaginal bleeding(97%) /anemia • Enlarged uterus (size > dates) • Pelvic pain • Theca lutein cysts • Hyperemesisgravidarum • Hyperthyroidism • Preeclampsia <20 weeks gestation • Vaginal passage of hydropic vesicles • Partial mole usually presented as incomplete or missed abortion

  11. Diagnosis • Complete : U/S usually very sensitive – generalized swelling (snow-storm ) • partial mole U/S may detect focal cystic spaces of varying diameter Diagnosis on histology of curettings

  12. Complete vs. partial mole

  13. Hydatidiform Mole Treatment • Evaluate for coexisting conditions: - History and physical - CBC, coagulation profile, serum chemistry - thyroid function - blood type and cross match - chest radiography - pelvic ultrasonography • Evacuation of mole - Suction curettage - Hysterectomy if completed childbearing • If Rh negative, give rhogham

  14. Hydatidiform Mole Treatment chemotherapy HM don’t need usually chemotherapy because HM is benign disease.

  15. Follow-Up Care – Molar Pregnancy • 80% of patients cured by evacuation • Follow B-hCG levels every two weeks until 3 consecutive tests negative • Then monthly B-hCG every month for 6-12 months • More than half of patients will have complete regression of hCG to normal within 2 months of evacuation. • Avoid pregnancy for at least 6 months after first normal B-hCG (oral contraceptive pills is preferable) • Subsequent Pregnancies: • Send placenta for pathology • Check B- hCG 6 weeks postpartum

  16. Prognosis • Complete mole has the latent risk of local invasion or telemetastasis • The high-risk factors includes • β-HCG>100000IU/L • uterine size is > 20 weeks size. • the luteinizing cyst is >6cm • If >40 years old,the risk of invasion and metastasis may be 37%, If >50 years old,the risk of invasion and metastasis may be 56%. • repeated mole: the morbidity of invasion and metastasis increase 3~4 times

  17. Gestational Trophoblastic Neoplasia (GTN) • Persistent/Invasive Mole • Choriocarcinoma • Placental-Site Trophoblastic Tumor (PSTT) ** Malignant

  18. Risk Factors for GTN After Mole • Preevacuation uterine size greater than gestationl age or larger than 20 weeks gestation • Theca-lutein cysts larger than 6 cm • Age > 40 years • Serum hCG levels > 100,000 mIU/mL • Previous hydatidiform mole

  19. Invasive Mole • Myometrial invasion by hydatidiform mole • Formerly known as chorioadenoma destruens • 1 in 15,000 pregnancies • 10-17% of hydatidiform moles will progress to invasive moles

  20. Persistent Mole Definition of persistent molar disease and need for chemotherapy (at least one of the following): • B-hCG plateau for ≥ 4 values for ≥ 3 weeks • B-hCG increase of ≥ 10% for ≥ 3 values for ≥ 2 weeks • B-hCG persistence 6 months after molar evacuation • Histopathologic diagnosis of choriocarcinoma • Presence of metastatic disease

  21. Choriocarcinoma • Most aggressive type of GTN • Abnormal trophoblastic hyperplasia • Absence of chorionic villi • Direct invasion of myometrium • Most often develops from a complete hydatidiform mole • Vascular spread to distant sites: • Lungs • Brain • Liver • Pelvis and vagina • Spleen, intestines, and kidney

  22. Choriocarcinoma • May come from any type of pregnancy - 25% follow abortion or tubal pregnancy - 25% with term gestation - 50% from hydatidiform moles • 2-3% of moles progress to choriocarcinoma • Incidence 1 in 40,000 pregnancies • Rarely, choriocarcinomas can develop in other parts of the body in both men and women. These are not related to pregnancy as ovaries and testicles • Nongestational choriocarcinoma tends to be less responsive to chemotherapy and has a less favorable prognosis than the gestational variant

  23. Placental-Site Trophoblastic Tumor (PSTT) • Originate from intermediate cytotrophoblast cells • Secrete human placental lactogen (hPL) • B-hCG often normal • Less vascular invasion, necrosis and hemorrhage than choriocarcinoma • Lymphatic spread • Arise months to years after term pregnancy but can occur after spontaneous abortion or molar pregnancy

  24. Placental-Site Trophoblastic Tumor (PSTT) • Most common symptom is vaginal bleeding • Tend to: - Remain in uterus - Disseminate late - Produce low levels of B-hCG compared to other GTN - Be resistant to chemotherapy (treat with surgery)

  25. Signs & Symptoms GTN • Continued uterine bleeding, uterine perforation, enlarged irregular uterus, persistent bilateral ovarian enlargement • From metastatic lesions: abdominal pain, hemoptysis, melena, increased intracranial pressure (headaches, seizures, hemiplegia), dyspnea, cough, chest pain

  26. Diagnosis of GTN • Increase or plateau in B-hCG after molar pregnancy • Pathologic diagnosis by D&C or biopsy of metastatic lesions • WARNING: biopsy of metastatic lesions can result in massive hemorrhage • Metastatic workup: CXR (or CT chest), CT abdomen/pelvis +/- CT/MR of brain

  27. Classification & Staging of GTD • FIGO Staging • Describes anatomic distribution of disease • World Health Organization (WHO) Scoring Index • Describes prognosis

  28. FIGO Staging

  29. The World Health Organization (WHO) scoring system for GTD

  30. WHO Prognostic Score Index

  31. Therapy for GTN • Single agent therapy for nonmetastatic (stage I) or low-risk metastatic (stage II and III) with score <7  survival rates ~ 100% • Combination chemotherapy +/- radiation and/or surgery for high-risk metastatic disease with score ≥7

  32. Therapy: Nonmetastatic GTN • Single-agent with either methotrexate or dactinomycin • Chemotherapy continued until hCG values normal and then 2-3 cycles beyond • Change to alternative single-agent for hCG plateaus above normal or toxicities • If significant elevation of hCG or new metastases, switch to multiagent • 85-90% cured with initial regimen, <5% will require hysterectomy for cure

  33. Therapy: Low-risk Metastatic GTN • Low-risk metastatic disease can be treated with single-agent therapy with 5-day regimens • Cure rates ~100% but 30-50% will be develop resistance to first agent • If resistance to sequential single-agent chemotherapy (5-10% of patients), switch to multiagent chemotherapy

  34. Therapy: High-risk Metastatic GTN • Stage IV • Stage II/III with score > 7 • Disease refractory to single-agent chemotherapy Combination Chemotherapy: • EMACO: • Day 1: Etoposide, Methotrexate and Dactinomycin • Day 8: Cyclophosphamide and Vincristine (Oncovorin) • Repeat q2 weeks until remission • Continue for at least 2-3 cycles beyond first normal hCG • MAC (Methotrexate, Dactinomycin, Cyclophosphamide) • EMA/EP – EMA + Etoposide and Cisplatin

  35. Metastatic Gestational Trophoblastic Tumors • Surgery • It is indicated for tumor resistant to chemotherapy and single metastases persisting despite chemotherapy. • RT • RT, in combination with chemotherapy, is clearly indicated for the primary management of patients with brain metastases.

  36. PSTT Therapy • Hysterectomy • Chemotherapy for metastatic disease or nonmetastatic disease with poor prognosis: - Interval from index pregnancy > 2 years - Deep myometrial invasion - Tumor necrosis - Mitotic count > 6 per 10 high-power fields • Survival rates: • ~100% for nonmetastatic disease • 50-60% for metastatic disease

  37. Follow-up Care • After completion of chemotherapy, follow serial hCG every 2 weeks for three months, then monthly for one year • Physical examinations every 6-12 months and imaging as indicated

  38. Reproductive Performance • Most women resume normal ovarian function • Women who undergo chemotherapy are advised not to conceive for one year after completion of treatment • No increase risk of stillbirths, abortions, congenital anomalies, prematurity, or major obstetric complications

  39. False Positive Serum hCG • Phantom hCG syndrome/ phantom choriocarcinoma • 3-4% of healthy individuals have human-antimouse antibodies that can mimic hCG immunoreactivity • To verify: • Urine hCG should be negative • Should not show parallel decrease with serial dilutions • Test at national B-hCG reference lab

  40. Summary • Hydatidiform mole is a benign condition, 80% cured with suction D&C • Malignant GTN: • Persistent or invasive mole • Choriocarcinoma • PSTT • WHO score > 7 represents high-risk disease • GTN very sensitive to chemotherapy

  41. Thank You For Your Time

More Related